Boehringer enriches cancer immunology portfolio with AMAL Therapeutics acquisition
AMAL’s lead vaccine, ATP128, is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month.
Read More
Tag: ATP128
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
